J9199 — Injection, gemcitabine hydrochloride (infugem), 200 mg
J9199 is a HCPCS Level II code for injection, gemcitabine hydrochloride (infugem), 200 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on June 30, 2020 and is not valid on new claims.
This code has been terminated
CMS terminated J9199 on June 30, 2020. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J9199
- Long descriptor
- Injection, gemcitabine hydrochloride (infugem), 200 mg
- Short descriptor
- Injection, infugem, 200 mg
- Added
- January 1, 2020
- Terminated
- June 30, 2020
- BETOS
- O1D
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J9199
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J9199 is not quite right, the correct code is very often within a few positions of it.
- J9179Injection, eribulin mesylate, 0.1 mg
- J9181Injection, etoposide, 10 mg
- J9183Gemcitabine intravesical system, 225 mg
- J9184Injection, gemcitabine hydrochloride (avyxa), 200 mg
- J9185Injection, fludarabine phosphate, 50 mg
- J9190Injection, fluorouracil, 500 mg
- J9196Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg
- J9198Injection, gemcitabine hydrochloride, (infugem), 100 mg
- J9200Injection, floxuridine, 500 mg
- J9201Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
- J9202Goserelin acetate implant, per 3.6 mg
- J9203Injection, gemtuzumab ozogamicin, 0.1 mg
- J9204Injection, mogamulizumab-kpkc, 1 mg
- J9205Injection, irinotecan liposome, 1 mg
- J9206Injection, irinotecan, 20 mg
- J9207Injection, ixabepilone, 1 mg
Questions about J9199
What is HCPCS code J9199?
J9199 is a HCPCS Level II code for injection, gemcitabine hydrochloride (infugem), 200 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J9199?
The CMS HCPCS file marks J9199 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is J9199 still valid?
No. J9199 was terminated on June 30, 2020 and should not be used on new claims.